Prepared by:
Blue Cross and Blue Shield Association
Technology Evaluation Center
Naomi Aronson, Ph.D.
Principal Investigator
Frank Lefevre, M.D.
Margaret Piper, Ph.D., M.P.H.
David Mark, M.D., M.P.H.
Rhonda Bohn, Ph.D.
Theodore Speroff, Ph.D.
Beth Finkelstein, Ph.D.
Investigators
File Name Description Software Version File Size __________________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 2002 49KB 7 pages Contents: Title Page, Preface, Structured Abstract __________________________________________________________________________________________________________ 02cont.doc Microsoft Word® Document MS Word® 2002 35KB 4 pages Contents: Table of Contents __________________________________________________________________________________________________________ 03summ.doc Microsoft Word® Document MS Word® 2002 86KB 15 pages Contents: Summary: Overview; Reporting the Evidence; Methodology; Findings; Future Research __________________________________________________________________________________________________________ 04chap1.doc Microsoft Word® Document MS Word® 2002 118KB 20 pages Contents: Chapter 1. Introduction: Definition of Asthma; Outcome Assessment of Asthma; Medications; Rationale and Background for Key Questions __________________________________________________________________________________________________________ 05chap2.doc Microsoft Word® Document MS Word® 2002 162KB 22 pages Contents: Chapter 2. Methodology: Overview; Methods of the Review; Meta-Analysis; Meta-Analysis Technical Supplement __________________________________________________________________________________________________________ 06chap3a.doc Microsoft Word® Document MS Word® 2002 504KB 47 pages Contents: Chapter 3. Results and Conclusions. Part 1: Long-Term Management of Asthma in Children __________________________________________________________________________________________________________ 07chap3b.doc Microsoft Word® Document MS Word® 2002 175KB 16 pages Contents: Chapter 3. Results and Conclusions. Part 2. Effects of Delayed ICS on Progression and Reversibility __________________________________________________________________________________________________________ 08chap3c.doc Microsoft Word® Document MS Word® 2002 1.0MB 62 pages Contents: Chapter 3. Results and Conclusions. Part 3. Addition of Other Long-Term Controller Medications to Inhaled Corticosteroids __________________________________________________________________________________________________________ 09chap3d.doc Microsoft Word® Document MS Word® 2002 45KB 4 pages Contents: Chapter 3. Results and Conclusions. Part 4. Effect of Antibiotics on Acute Asthma Exacerbations __________________________________________________________________________________________________________ 10chap3e.doc Microsoft Word® Document MS Word® 2002 523KB 38 pages Contents: Chapter 3. Results and Conclusions. Part 5. Asthma Management Plans __________________________________________________________________________________________________________ 11chap4.doc Microsoft Word® Document MS Word® 2002 31KB 3 pages Contents: Chapter 4. Future Research Priorities __________________________________________________________________________________________________________ 12refs.doc Microsoft Word® Document MS Word® 2002 94KB 10 pages Contents: References __________________________________________________________________________________________________________ 13etblsa.doc Microsoft Word® Document MS Word® 2002 574KB 26 pages Contents: Evidence Tables. Part 1: Evidence Table 1-1. Study characteristics Evidence Table 1-2. Study parameters Evidence Table 1-3. Population characteristics Evidence Table 1-4. Lung function outcomes: FEV1 Evidence Table 1-5. Lung function outcomes: PEF Evidence Table 1-6. Lung function outcomes: PC20 Evidence Table 1-7. Symptom score outcomes Evidence Table 1-8. Symptom frequency and exacerbation outcomes Evidence Table 1-9. Medication use outcomes Evidence Table 1-10. Utilization outcomes __________________________________________________________________________________________________________ 14etblsb.doc Microsoft Word® Document MS Word® 2002 179KB 10 pages Contents: Evidence Tables. Part 2: Evidence Table 2-1. Study characteristics Evidence Table 2-2. Study parameters Evidence Table 2-3. Population characteristics Evidence Table 2-4. Lung function outcomes: FEV1 Evidence Table 2-5. Lung function outcomes: PEF Evidence Table 2-6. Lung function outcomes: Bronchial hyperreactivity Evidence Table 2-7. Symptoms/medications outcomes __________________________________________________________________________________________________________ 15etblsc.doc Microsoft Word® Document MS Word® 2002 2.2MB 91 pages Contents: Evidence Tables. Part 3: Evidence Table 3-1. Study characteristics Evidence Table 3-2. Study treatment arms Evidence Table 3-3. Population Characteristics Evidence Table 3-4. Lung function outcomes. FEV1 Evidence Table 3-5. Lung function outcomes. PEF Evidence Table 3-6. Lung function outcomes. PC20 Evidence Table 3-7. Medication Use Outcomes Evidence Table 3-8. Symptom score outcomes Evidence Table 3-9. Symptom frequency and exacerbation outcomes Evidence Table 3-10. Quality of life outcomes Evidence Table 3-11. Adverse events summary Meta-Analysis Table 3-12. FEV1. Studies comparing the addition of long-acting beta-agonists to a fixed ICS dose Meta-Analysis Table 3-13. PEF. Studies comparing the addition of long-acting beta-agonists to a fixed ICS dose Meta-Analysis Table 3-14. Puffs/day. Studies comparing the addition of long-acting beta-agonists to a fixed ICS dose Meta-Analysis Table 3-15. FEV1. Studies comparing a lower ICS Dose + long-acting beta-agonists vs. an increased ICS dose Meta-Analysis Table 3-16. PEF. Studies comparing a lower ICS dose + long-acting beta-agonists vs. an increased ICS dose Meta-Analysis Table 3-17. Puffs/day. Studies comparing a lower ICS dose + long-acting beta-agonists vs. an increased ICS dose Meta-Analysis Table 3-18. Stratification by treatment duration, age, and baseline FEV1 for studies comparing the addition of long-acting beta-agonists to a fixed ICS dose Meta-Analysis Table 3-19. Identification of studies by stratum for analysis results presented in Table 3-18 Meta-Analysis Table 3-20. Stratification by treatment duration, age, and baseline FEV1 for studies comparing a lower ICS dose + long-acting beta-agonists vs. an increased ICS dose Meta-Analysis Table 3-21. Identification of studies by stratum for analysis results presented in Table 3-20 __________________________________________________________________________________________________________ 16etblsd.doc Microsoft Word® Document MS Word® 2002 66KB 5 pages Contents: Evidence Tables. Part 4: Evidence Table 4-1. Study characteristics Evidence Table 4-2. Study parameters Evidence Table 4-3. Population characteristics Evidence Table 4-4. Lung function outcomes Evidence Table 4-5. Symptoms/utilization outcomes __________________________________________________________________________________________________________ 17etblse.doc Microsoft Word® Document MS Word® 2002 468KB 21 pages Contents: Evidence Tables. Part 5: Evidence Table 5-1. Study characteristics Evidence Table 5-2. Study parameters Evidence Table 5-3. Population characteristics Evidence Table 5-4. Lung function outcomes. FEV1 Evidence Table 5-5. Lung function outcomes. PEF Evidence Table 5-6. Medication Outcomes Evidence Table 5-7. Symptom score outcomes Evidence Table 5-8. Symptom frequency and exacerbation outcomes Evidence Table 5-9. Utilization outcomes __________________________________________________________________________________________________________ 18biblio.doc Microsoft Word® Document MS Word® 2002 280KB 35 pages Contents: Bibliography __________________________________________________________________________________________________________ 19appa.doc Microsoft Word® Document MS Word® 2002 41KB 5 pages Contents: Appendix A. Technical Advisory Group Peer Reviewers Medical Advisory Panel __________________________________________________________________________________________________________ 20appb.doc Microsoft Word® Document MS Word® 2002 27KB 3 pages Contents: Appendix B. Search Strategy Details __________________________________________________________________________________________________________ 21appc.doc Microsoft Word® Document MS Word® 2002 70KB 2 pages Contents: Appendix C. Acronyms and Abbreviations __________________________________________________________________________________________________________
AHRQ Publication No. 01-E044
Current as of September 2001
Internet Citation:
Management of Chronic Asthma. File Inventory, Evidence Report/Technology Assessment Number 44. AHRQ Publication No. 01-E044, September 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/astmainv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services